297 related articles for article (PubMed ID: 24053720)
1. Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.
Ioannou K; Derhovanessian E; Tsakiri E; Samara P; Kalbacher H; Voelter W; Trougakos IP; Pawelec G; Tsitsilonis OE
BMC Immunol; 2013 Sep; 14():43. PubMed ID: 24053720
[TBL] [Abstract][Full Text] [Related]
2. Prothymosin alpha immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner.
Skopeliti M; Iconomidou VA; Derhovanessian E; Pawelec G; Voelter W; Kalbacher H; Hamodrakas SJ; Tsitsilonis OE
Mol Immunol; 2009 Feb; 46(5):784-92. PubMed ID: 18976813
[TBL] [Abstract][Full Text] [Related]
3. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.
Voutsas IF; Pistamaltzian N; Tsiatas ML; Skopeliti M; Katsila T; Mavrothalassiti I; Spyrou S; Dimopoulos MA; Tsitsilonis OE; Bamias A
Eur J Cancer; 2013 May; 49(7):1706-14. PubMed ID: 23276721
[TBL] [Abstract][Full Text] [Related]
4. Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction.
Mosoian A; Teixeira A; Burns CS; Sander LE; Gusella GL; He C; Blander JM; Klotman P; Klotman ME
Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10178-83. PubMed ID: 20479248
[TBL] [Abstract][Full Text] [Related]
5. Prothymosin Alpha: A Novel Contributor to Estradiol Receptor Alpha-Mediated CD8
Passos LSA; Jha PK; Becker-Greene D; Blaser MC; Romero D; Lupieri A; Sukhova GK; Libby P; Singh SA; Dutra WO; Aikawa M; Levine RA; Nunes MCP; Aikawa E
Circulation; 2022 Feb; 145(7):531-548. PubMed ID: 35157519
[TBL] [Abstract][Full Text] [Related]
6. Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas.
Voutsas IF; Baxevanis CN; Gritzapis AD; Missitzis I; Stathopoulos GP; Archodakis G; Banis C; Voelter W; Papamichail M
Cancer Immunol Immunother; 2000 Oct; 49(8):449-58. PubMed ID: 11043852
[TBL] [Abstract][Full Text] [Related]
7. Prothymosin Alpha: An Alarmin and More..
Samara P; Karachaliou CE; Ioannou K; Papaioannou NE; Voutsas IF; Zikos C; Pirmettis I; Papadopoulos M; Kalbacher H; Livaniou E; Tsitsilonis OE; Voelter W
Curr Med Chem; 2017; 24(17):1747-1760. PubMed ID: 28521686
[TBL] [Abstract][Full Text] [Related]
8. Late dendritic cells are still able to evoke a potent alloreactive CTL response.
Repnik U; Bergant M; Wraber B; Jeras M
Immunobiology; 2008; 213(1):51-64. PubMed ID: 18207027
[TBL] [Abstract][Full Text] [Related]
9. Prothymosin-α Variants Elicit Anti-HIV-1 Response via TLR4 Dependent and Independent Pathways.
Gusella GL; Teixeira A; Aberg J; Uversky VN; Mosoian A
PLoS One; 2016; 11(6):e0156486. PubMed ID: 27310139
[TBL] [Abstract][Full Text] [Related]
10. Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?
Samara P; Ioannou K; Tsitsilonis OE
Vitam Horm; 2016; 102():179-207. PubMed ID: 27450735
[TBL] [Abstract][Full Text] [Related]
11. Prothymosin-alpha preconditioning activates TLR4-TRIF signaling to induce protection of ischemic retina.
Halder SK; Matsunaga H; Ishii KJ; Ueda H
J Neurochem; 2015 Dec; 135(6):1161-77. PubMed ID: 26364961
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells activated by an anti-inflammatory agent induce CD4(+) T helper type 2 responses without impairing CD8(+) memory and effector cytotoxic T-lymphocyte responses.
Wang Y; Da'Dara AA; Thomas PG; Harn DA
Immunology; 2010 Mar; 129(3):406-17. PubMed ID: 19922421
[TBL] [Abstract][Full Text] [Related]
13. Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.
Pathangey LB; McCurry DB; Gendler SJ; Dominguez AL; Gorman JE; Pathangey G; Mihalik LA; Dang Y; Disis ML; Cohen PA
Oncotarget; 2017 Feb; 8(7):10785-10808. PubMed ID: 27974697
[TBL] [Abstract][Full Text] [Related]
14. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
15. The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients.
Skopeliti M; Voutsas IF; Klimentzou P; Tsiatas ML; Beck A; Bamias A; Moraki M; Livaniou E; Neagu M; Voelter W; Tsitsilonis OE
Cancer Immunol Immunother; 2006 Oct; 55(10):1247-57. PubMed ID: 16453152
[TBL] [Abstract][Full Text] [Related]
16. Evidence for ProTα-TLR4/MD-2 binding: molecular dynamics and gravimetric assay studies.
Omotuyi O; Matsunaga H; Ueda H
Expert Opin Biol Ther; 2015; 15 Suppl 1():S223-9. PubMed ID: 25604147
[TBL] [Abstract][Full Text] [Related]
17. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
[TBL] [Abstract][Full Text] [Related]
18. An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells.
Tomasicchio M; Semple L; Esmail A; Meldau R; Randall P; Pooran A; Davids M; Cairncross L; Anderson D; Downs J; Malherbe F; Novitzky N; Panieri E; Oelofse S; Londt R; Naiker T; Dheda K
Cancer Immunol Immunother; 2019 Jan; 68(1):71-83. PubMed ID: 30283982
[TBL] [Abstract][Full Text] [Related]
19. Critical role of TRIF and MyD88 in Mycobacterium tuberculosis Hsp70-mediated activation of dendritic cells.
Kim TH; Shin SJ; Park YM; Jung ID; Ryu SW; Kim DJ; Park JH; Park JH
Cytokine; 2015 Feb; 71(2):139-44. PubMed ID: 25461391
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
Baxevanis CN; Voutsas IF; Tsitsilonis OE; Gritzapis AD; Sotiriadou R; Papamichail M
J Immunol; 2000 Apr; 164(7):3902-12. PubMed ID: 10725753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
